Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial

J Am Acad Dermatol. 2014 Mar;70(3):583-4. doi: 10.1016/j.jaad.2013.11.007.

Authors

Lauren Okon¹, Misha Rosenbach¹, Michael Krathen¹, Mathew Rose¹, Kathleen Propert², Joyce Okawa¹, Victoria Werth³

Affiliations

¹ Philadelphia Veterans Affairs Medical Center, Philadelphia, PA; Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
² Department of Biostatistics at HUP, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
³ Philadelphia Veterans Affairs Medical Center, Philadelphia, PA; Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. Electronic address: werth@mail.med.upenn.edu.

No abstract available

Publication types

Clinical Trial
Letter
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Administration, Oral
Biopsy, Needle
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Immunohistochemistry
Lenalidomide
Lupus Erythematosus, Cutaneous / drug therapy*
Lupus Erythematosus, Cutaneous / pathology*
Male
Patient Safety*
Prospective Studies
Severity of Illness Index
Thalidomide / analogs & derivatives*
Thalidomide / therapeutic use
Time Factors
Treatment Outcome

Substances

Thalidomide
Lenalidomide

Associated data

ClinicalTrials.gov/NCT00633945

Grants and funding